IgE as adjuvant in tumor vaccination

Elisa A. Nigro, Antonio G. Siccardi, Luca Vangelista

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Activation of the antigen-IgE-FcεRI axis results in a potent inflammatory state. The redirection of this IgE-mediated activation of the immune system from allergic reactions toward tumors is the main theme of the new AllergoOncology field. Our particular approach has been to employ IgE as an adjuvant in anti-tumor vaccination. IgE-coated tumor cells can protect against tumor challenge, an observation that supports the involvement of IgE in anti-tumor immunity. The adjuvant effect of IgE was shown to result from eosinophil-dependent priming of the T-cell-mediated adaptive immune response. Moreover, the role of FcεRI in IgE anti-tumor adjuvanticity has been recently demonstrated. The interaction of tumor cell-bound IgE with receptors triggers the release of mediators with following recruitment of effector cells, cell killing and tumor antigen cross-priming. Starting from these evidences, several improvements toward a simple and universal use of IgE in anti-tumor cellular vaccines have been accomplished. In view of narrowing the gap between experimental models and therapeutic applications, the field is now shifting toward a humanized systems, employing human IgE and human FcεRIα transgenic mice.

Original languageEnglish
Title of host publicationCancer and IgE: Introducing the Concept of AllergoOncology
PublisherHumana Press
Pages215-229
Number of pages15
ISBN (Print)9781607614500
DOIs
Publication statusPublished - 2010
Externally publishedYes

Fingerprint

Immunoglobulin E
Tumors
Vaccination
Neoplasms
Cells
Cross-Priming
IgE Receptors
Cancer Vaccines
Chemical activation
Adaptive Immunity
Neoplasm Antigens
Eosinophils
Cell Communication
Transgenic Mice
T-cells
Immune system
Immune System
Immunity
Hypersensitivity
Theoretical Models

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Nigro, E. A., Siccardi, A. G., & Vangelista, L. (2010). IgE as adjuvant in tumor vaccination. In Cancer and IgE: Introducing the Concept of AllergoOncology (pp. 215-229). Humana Press. https://doi.org/10.1007/978-1-60761-451-7_9

IgE as adjuvant in tumor vaccination. / Nigro, Elisa A.; Siccardi, Antonio G.; Vangelista, Luca.

Cancer and IgE: Introducing the Concept of AllergoOncology. Humana Press, 2010. p. 215-229.

Research output: Chapter in Book/Report/Conference proceedingChapter

Nigro, EA, Siccardi, AG & Vangelista, L 2010, IgE as adjuvant in tumor vaccination. in Cancer and IgE: Introducing the Concept of AllergoOncology. Humana Press, pp. 215-229. https://doi.org/10.1007/978-1-60761-451-7_9
Nigro EA, Siccardi AG, Vangelista L. IgE as adjuvant in tumor vaccination. In Cancer and IgE: Introducing the Concept of AllergoOncology. Humana Press. 2010. p. 215-229 https://doi.org/10.1007/978-1-60761-451-7_9
Nigro, Elisa A. ; Siccardi, Antonio G. ; Vangelista, Luca. / IgE as adjuvant in tumor vaccination. Cancer and IgE: Introducing the Concept of AllergoOncology. Humana Press, 2010. pp. 215-229
@inbook{9ccfa8a57bf64470bd9fbce9f3c90e99,
title = "IgE as adjuvant in tumor vaccination",
abstract = "Activation of the antigen-IgE-FcεRI axis results in a potent inflammatory state. The redirection of this IgE-mediated activation of the immune system from allergic reactions toward tumors is the main theme of the new AllergoOncology field. Our particular approach has been to employ IgE as an adjuvant in anti-tumor vaccination. IgE-coated tumor cells can protect against tumor challenge, an observation that supports the involvement of IgE in anti-tumor immunity. The adjuvant effect of IgE was shown to result from eosinophil-dependent priming of the T-cell-mediated adaptive immune response. Moreover, the role of FcεRI in IgE anti-tumor adjuvanticity has been recently demonstrated. The interaction of tumor cell-bound IgE with receptors triggers the release of mediators with following recruitment of effector cells, cell killing and tumor antigen cross-priming. Starting from these evidences, several improvements toward a simple and universal use of IgE in anti-tumor cellular vaccines have been accomplished. In view of narrowing the gap between experimental models and therapeutic applications, the field is now shifting toward a humanized systems, employing human IgE and human FcεRIα transgenic mice.",
author = "Nigro, {Elisa A.} and Siccardi, {Antonio G.} and Luca Vangelista",
year = "2010",
doi = "10.1007/978-1-60761-451-7_9",
language = "English",
isbn = "9781607614500",
pages = "215--229",
booktitle = "Cancer and IgE: Introducing the Concept of AllergoOncology",
publisher = "Humana Press",
address = "United States",

}

TY - CHAP

T1 - IgE as adjuvant in tumor vaccination

AU - Nigro, Elisa A.

AU - Siccardi, Antonio G.

AU - Vangelista, Luca

PY - 2010

Y1 - 2010

N2 - Activation of the antigen-IgE-FcεRI axis results in a potent inflammatory state. The redirection of this IgE-mediated activation of the immune system from allergic reactions toward tumors is the main theme of the new AllergoOncology field. Our particular approach has been to employ IgE as an adjuvant in anti-tumor vaccination. IgE-coated tumor cells can protect against tumor challenge, an observation that supports the involvement of IgE in anti-tumor immunity. The adjuvant effect of IgE was shown to result from eosinophil-dependent priming of the T-cell-mediated adaptive immune response. Moreover, the role of FcεRI in IgE anti-tumor adjuvanticity has been recently demonstrated. The interaction of tumor cell-bound IgE with receptors triggers the release of mediators with following recruitment of effector cells, cell killing and tumor antigen cross-priming. Starting from these evidences, several improvements toward a simple and universal use of IgE in anti-tumor cellular vaccines have been accomplished. In view of narrowing the gap between experimental models and therapeutic applications, the field is now shifting toward a humanized systems, employing human IgE and human FcεRIα transgenic mice.

AB - Activation of the antigen-IgE-FcεRI axis results in a potent inflammatory state. The redirection of this IgE-mediated activation of the immune system from allergic reactions toward tumors is the main theme of the new AllergoOncology field. Our particular approach has been to employ IgE as an adjuvant in anti-tumor vaccination. IgE-coated tumor cells can protect against tumor challenge, an observation that supports the involvement of IgE in anti-tumor immunity. The adjuvant effect of IgE was shown to result from eosinophil-dependent priming of the T-cell-mediated adaptive immune response. Moreover, the role of FcεRI in IgE anti-tumor adjuvanticity has been recently demonstrated. The interaction of tumor cell-bound IgE with receptors triggers the release of mediators with following recruitment of effector cells, cell killing and tumor antigen cross-priming. Starting from these evidences, several improvements toward a simple and universal use of IgE in anti-tumor cellular vaccines have been accomplished. In view of narrowing the gap between experimental models and therapeutic applications, the field is now shifting toward a humanized systems, employing human IgE and human FcεRIα transgenic mice.

UR - http://www.scopus.com/inward/record.url?scp=84855390024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855390024&partnerID=8YFLogxK

U2 - 10.1007/978-1-60761-451-7_9

DO - 10.1007/978-1-60761-451-7_9

M3 - Chapter

SN - 9781607614500

SP - 215

EP - 229

BT - Cancer and IgE: Introducing the Concept of AllergoOncology

PB - Humana Press

ER -